Cutaneous toxicities of targeted therapies in the treatment of hepatocellular carcinoma

Abstract

Liver cancer accounts for 4.7% of all newly diagnosed cancers and 8.2% of cancer deaths annu-ally. Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. There are 2 curative strategies in HCC: resection and transplant. Unfortunately, 50% of patients who undergo resection will relapse in 2 years and many patients on transplant lists become ineligible for transplant due to disease progression. The majority of patients still require systemic therapies. Tyrosine kinase inhibitors have successfully extended the overall survival in patients with hepa-tocellular carcinoma. However, these treatments have been noted to cause severe side effects in-cluding liver toxicity, hypertension, gastrointestinal toxicity and cutaneous adverse effects. This article will focus on the adverse skin reactions seen during the treatment of hepatocellular carci-noma by various tyrosine kinase inhibitors. The focus will be symptomatology, management, and whether the development of cutaneous toxicities can be prognostic.

Keywords

Hepatocellular cancer / tyrosine kinase inhibitors / cutaneous toxicity / hand foot reaction syndrome

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Villanueva A.Hepatocellular carcinoma..N Engl J Med2019;380:1450-62

[3] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[4] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[5] Bruix J,Merle P,Huang Y.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[6] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63 PMCID:PMC7523244

[7] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[8] Reyes-Habito CM.Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy..J Am Acad Dermatol2014;71:217.e1-11quiz 227-8

[9] Chu D,Fillos T.Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis..Acta Oncol2008;47:176-86

[10] Dranitsaris G,Yu J,Fang F.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib..Ann Oncol2012;23:2103-8 PMCID:PMC3403729

[11] Cheng A,Chen Z,Qin S.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[12] Zhang HL,Wang HK,Ma CG.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study..Oncotarget2015;6:36870-83 PMCID:PMC4742216

[13] Lipworth AD,Zhu AX.Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib..Oncology2009;77:257-71

[14] McLellan B,Lacouture ME,Van Cutsem E.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management..Ann Oncol2015;26:2017-26 PMCID:PMC4576906

[15] Zuo RC,DiGiovanna JJ,Keen CM.Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib..JAMA Dermatol2015;151:170-7 PMCID:PMC6776420

[16] Reed N,Gerrard G,Lei M.Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer..Clin Oncol (R Coll Radiol)2020;32:e145-53

[17] Jacobi U,Schulze P,Oskay-Ozcelik G.Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?.Ann Oncol2005;16:1210-1

[18] Lacouture ME,Robert C,Kong HH.Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib..Oncologist2008;13:1001-11

[19] Ai L,Yang B,Luo P.Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management..Expert Rev Clin Pharmacol2019;12:1121-7

[20] Anderson R,Robert C,Keating KN.Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)..Oncologist2009;14:291-302

[21] Ren Z,Kang H,Qu Z.Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma..J Clin Oncol2015;33:894-900

[22] Brose MS,Keefe SM.Management of sorafenib-related adverse events: a clinician's perspective..Semin Oncol.2014;41 Suppl 2:S1-16

[23] Common Terminology Criteria for Adverse Events (CTCAE) v5. US Department of health and human services. National Institute of Health. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. [Last accessed on 30 Sep 2020]

[24] Vukelja SJ,James WD.Pyridoxine for the palmar-plantar erythrodysesthesia syndrome..Ann Intern Med1989;111:688-9

[25] Lacouture ME,Gerami P.Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib..Ann Oncol2008;19:1955-61

[26] Autier J,Wechsler J,Robert C.Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor..Arch Dermatol2008;144:886-92

[27] Lee WJ,Chang SE,Kang YK.Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib..Br J Dermatol2009;161:1045-51

[28] Haddad RI,Wirth LJ,Shah MH.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes..Endocrine2017;56:121-8 PMCID:PMC5368192

[29] Wood LS.Managing the side effects of sorafenib and sunitinib..Commun Oncol2006;3:558-62

[30] Pérez-Soler R,Halpern A,Krueger J.HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum..Oncologist2005;10:345-56

[31] Sarkodie T.Late presentation of sorafenib-associated rash: a case report..J Med Case Rep2010;4:338 PMCID:PMC2974748

[32] Çalışkan S.Sorafenib-induced Scrotal Eczema..Rev Urol2015;17:250-1 PMCID:PMC4735673

[33] Ishak RS,Kyei A.Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors..Crit Rev Oncol Hematol2014;90:152-64

[34] De Wit M,Saettini A,de Juan CR.Prevention and management of adverse events related to regorafenib..Support Care Cancer2014;22:837-46 PMCID:PMC3913844

[35] Harris DJ,Harriman A,Maxwell C.Putting evidence into practice: evidence-based interventions for the management of oral mucositis..Clin J Oncol Nurs2008;12:141-52

[36] Bensinger W,Ang KK,Brown E.Prevention and management of mucositis in cancer care..J Natl Compr Canc Netw.2008;6 Suppl 1:S1-21

[37] Califano R,Compton S,Harwood CA.Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK..Drugs2015;75:1335-48 PMCID:PMC4532717

[38] Bayer HealthCare Pharmaceuticals Inc. Nexavar (Sorafenib) [package insert]. U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf. [Last accessed on 24 Sep 2017]

[39] Guggina LM,Choi JN.EGFR inhibitors and cutaneous complications: a practical approach to management..Oncol Ther2017;5:135-48

[40] Sohn KH,Lim KW,Lee SY.Sorafenib induces delayed-onset cutaneous hypersensitivity: a case series..Allergy Asthma Immunol Res2015;7:304-7 PMCID:PMC4397373

[41] Mantovani A.Anaphylaxis preceded by erythema multiforme with sorafenib: first case report..Ann Hepatol2019;18:777-9

[42] Trayes KP,Studdiford JS.Erythema multiforme: recognition and management..Am Fam Physician2019;100:82-88

[43] Ayangco L.Oral manifestations of erythema multiforme..Dermatol Clin2003;21:195-205

[44] Sokumbi O.Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist..Int J Dermatol2012;51:889-902

[45] Choi MK,Heo J,Kim GH.Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma..Ann Dermatol2011;23:S404-7 PMCID:PMC3276809

[46] Dodiuk-Gad RP,Valeyrie-Allanore L.Stevens-johnson syndrome and toxic epidermal necrolysis: an update..Am J Clin Dermatol2015;16:475-93

[47] Duong TA,Wolkenstein P.Severe cutaneous adverse reactions to drugs..Lancet2017;390:1996-2011

[48] Kardaun SH.Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis..Acta Derm Venereol2007;87:144-8

[49] Valeyrie-Allanore L,Brochard L,Maître B.Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis..Br J Dermatol2010;163:847-53

[50] Paradisi A,Bergamo F,Didona D.Etanercept therapy for toxic epidermal necrolysis..J Am Acad Dermatol2014;71:278-83

[51] Kannaiyan R.A comprehensive review of protein kinase inhibitors for cancer therapy..Expert Rev Anticancer Ther2018;18:1249-70 PMCID:PMC6322661

[52] Autier J,Wechsler J,Robert C.Cutaneous side effects of sorafenib and sunitinib..Ann Dermatol Venereol2008;135:148-53quiz 147, 154

[53] Eisai Inc. Lenvima (Lenvatinib) [package insert]. U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf. [Last accessed on 24 Sep 2020]

[54] Choueiri TK,Powles T,Mainwaring PN.Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial..Lancet Oncol2016;17:917-27

[55] Exelixis. Cabometyx (Cabozantinib) [package insert]. U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf. [Last accessed on 24 Sep 2020]

[56] Finn RS,Granito A,Bodoky G.Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial..J Hepatol2018;69:353-8

[57] Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. Available from: https://doi.org/10.1200/jco.2013.31.15_suppl.3637. [Last accessed on 30 Sep 2020]

[58] Sastre J,Benavides M,García-Alfonso P.Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer..Clin Transl Oncol2014;16:942-53 PMCID:PMC4194027

[59] Khan G,Braiteh F.Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management..Cancer Manag Res2014;6:93-103 PMCID:PMC3949557

[60] Grothey A,van Cutsem E,Sobrero A.Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care..Oncologist2014;19:669-80 PMCID:PMC4041675

[61] Mitchell J,McNeal D.Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer..Clin J Oncol Nurs2014;18:E19-25

[62] Bayer HealthCare Pharmaceuticals Inc. Stivarga (Regorafenib). U.S. Food and Drug Administration website. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204369lbl.pdf. [Last accessed on 24 Sep 2020]

[63] Vincenzi B,Russo A,Giuliani F.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib..Oncologist2010;15:85-92 PMCID:PMC3227883

[64] Shomura M,Shiraishi K,Arase Y.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma..World J Hepatol2014;6:670-6 PMCID:PMC4179146

[65] Sung MW,Qin S,Ikeda K.Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)..JCO2019;37:317

[66] Abou-alfa GK,Cheng A,Bolondi L.Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial..JCO2019;37:4088

[67] Wakatsuki T,Suenaga M,Matsushima T.Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC)..JCO2017;35:556

[68] Rimassa L,Pressiani T.Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma..Cancer Treat Rev2019;77:20-8

[69] Kong Y,Hou Z,Chen P.Apatinib is effective for treatment of advanced hepatocellular carcinoma..Oncotarget2017;8:105596-605 PMCID:PMC5739662

[70] Liu J,Zhang H,Chen H.Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial..Pharmazie2019;74:688-93